Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK completes acquisition of Sierra Oncology
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
GSK today announced the first recipient of the Target the Future Think Tank Challenge.
Japan’s Ministry of Health, Labour and Welfare accepts Shingrix regulatory submission to prevent shingles in at-risk adults aged 18 years and older
Shingrix was initially approved in 2018 by the Japanese MHLW to prevent shingles in adults aged 50 years or older
GSK presents promising new data for bepirovirsen, an investigational treatment for chronic hepatitis B
GSK today announced interim results from the B-Clear phase IIb trial at the EASL International Liver Congress.
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
GSK announced £1bn investment over ten years to accelerate R&D dedicated to infectious diseases
GSK to present new data from the B-Clear phase IIb trial for bepirovirsen in chronic hepatitis B at the International Liver Congress 2022
GSK will present 12 abstracts at the European Association for the Study of the Liver’s International Liver Congress 2022.
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK today announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon
The proposed Demerger is the most significant corporate change for GSK in the last 20 years
GSK publishes Prospectus and Circular for proposed demerger of its Consumer Healthcare business to form Haleon
The Circular is available at www.gsk.com/demerger and the Prospectus is available at www.haleon.com
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
Supports development of a strong portfolio of innovative vaccines and specialty medicines
ViiV Healthcare announces marketing approval by Japan’s Ministry of Health, Labour and Welfare for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine)
Long-acting treatment enables people living with HIV to reduce the days they receive treatment.
GSK announces further appointments to Designate Haleon Board
Demerger and listing of Haleon expected in July 2022
China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus
China’s National Medical Products Administration has approved a two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years.
ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure
GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA
GSK plc will present 25 abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director
GSK has announced that Dr Vishal Sikka, founder and CEO of Vianai Systems, will join the Board of the Company as a Non-Executive Director.
SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea
SK submits license application to MFDS to support vaccine sovereignty in South Korea
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand
US Food and Drug Administration accepts New Drug Application for daprodustat
US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat